JAK1 Inhibitor Promising for Refractory Crohn's |
Journal Updates
eMediNexus Coverage from: 
JAK1 Inhibitor Promising for Refractory Crohn's

0 Read Comments                

The JAK-1 inhibitor upadacitinib was found to be superior to placebo in inducing endoscopic remission in refractory Crohns disease (CD) patients in the phase II randomized CELEST trial.

Investigators reported that while no placebo patients achieved endoscopic remission, patients across different treatment dose groups did so. Rates of clinical remission were as follows among dosage groups: 13% of those receiving 3 mg of upadacitinib twice daily; 27% of those receiving 6 mg of upadacitinib twice daily; 11% of those receiving 12 mg twice daily; 22% of those receiving 24 mg twice daily; 14% of those receiving 24 mg once daily; 11% of those receiving placebo. The findings were published online in Gastroenterology.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now